Introduction

---

Berlex Laboratories, Incorporated is a research-based pharmaceutical company headquartered in Montville, New Jersey with operations in Wayne, New Jersey; Bothell, Washington; Seattle, Washington; and Richmond, California. Berlex is the US affiliate of Schering AG, headquartered in Berlin, Germany. While its parent company bears a similar name, Berlex is in no way affiliated with the US-headquartered pharmaceutical company Schering-Plough. In 2004 Berlex recorded US sales of $ 1.3 billion, accounting for 25% Schering AG's global sales. Approximately 1/3 of Schering's research takes place in the US under the purview of Berlex's Biosciences division. Berlex employs approximately 2,400 people in the United States.

Products

---

As of 2006, the Berlex portfolio consists of 19 Food and Drug Administration (FDA)-approved drugs within the business areas of female healthcare, diagnostic imaging, oncology, and therapies related to the treatment of cardiovascular and neurological conditions. These products are:

• Angeliq® (drospirenone and estradiol)
• Betapace AF® (sotalol HCI)
• Betapace® (sotalol HCI)
• Betaseron® (interferon beta-1b)
• Campath® (alemtuzumab)
• Climara Pro™ (estradiol/levonorgestrel transdermal system)
• Climara® (estradiol transdermal system)
• Feridex I.V.® (ferumoxides injectable solution)
• Fludara® (fludarabine phospate)
• Leukine® (sargramostim)
• Levlen® 28 (levonorgestrel and ethinyl estradiol tablets)
• Levlite® (levonorgestrel and ethinyl estradiol tablets)
• Magnevist® (gadopentetate dimeglumine)
• Menostar™ (estradiol transdermal system)
• Mirena® (levonorgestrel-releasing intrauterine system)
• Refludan® (lepirudin)
• Tri-Levlen® 28 (levonorgestrel and ethinyl estradiol tablets)
• Ultravist® (iopromide)
• Yasmin® (drospirenone and ethinyl estradiol tablets)

Research and Development

---

According to its website, Berlex's current research and development is focused in the same areas as its extant, FDA-approved products: diagnostic imaging, therapeutics, gender-specific healthcare, and oncology. Berlex claims to have in its product pipeline at least 8 oncology drugs in various stages of development.

References

---

1. http://www.berlex.com

Companies based in New Jersey | Biotechnology companies | Pharmaceutical companies